全文获取类型
收费全文 | 47858篇 |
免费 | 3537篇 |
国内免费 | 1483篇 |
专业分类
耳鼻咽喉 | 291篇 |
儿科学 | 1127篇 |
妇产科学 | 640篇 |
基础医学 | 7778篇 |
口腔科学 | 981篇 |
临床医学 | 3338篇 |
内科学 | 7704篇 |
皮肤病学 | 971篇 |
神经病学 | 3855篇 |
特种医学 | 687篇 |
外国民族医学 | 5篇 |
外科学 | 3797篇 |
综合类 | 6502篇 |
现状与发展 | 4篇 |
预防医学 | 2246篇 |
眼科学 | 535篇 |
药学 | 6861篇 |
4篇 | |
中国医学 | 2150篇 |
肿瘤学 | 3402篇 |
出版年
2024年 | 105篇 |
2023年 | 836篇 |
2022年 | 2058篇 |
2021年 | 1977篇 |
2020年 | 1536篇 |
2019年 | 1624篇 |
2018年 | 1629篇 |
2017年 | 1590篇 |
2016年 | 1504篇 |
2015年 | 1594篇 |
2014年 | 2602篇 |
2013年 | 2856篇 |
2012年 | 2452篇 |
2011年 | 2913篇 |
2010年 | 2371篇 |
2009年 | 2351篇 |
2008年 | 2366篇 |
2007年 | 2138篇 |
2006年 | 1979篇 |
2005年 | 1861篇 |
2004年 | 1732篇 |
2003年 | 1448篇 |
2002年 | 1207篇 |
2001年 | 919篇 |
2000年 | 938篇 |
1999年 | 781篇 |
1998年 | 643篇 |
1997年 | 700篇 |
1996年 | 690篇 |
1995年 | 649篇 |
1994年 | 551篇 |
1993年 | 424篇 |
1992年 | 297篇 |
1991年 | 306篇 |
1990年 | 223篇 |
1989年 | 191篇 |
1988年 | 189篇 |
1987年 | 150篇 |
1986年 | 154篇 |
1985年 | 293篇 |
1984年 | 310篇 |
1983年 | 242篇 |
1982年 | 274篇 |
1981年 | 214篇 |
1980年 | 198篇 |
1979年 | 181篇 |
1978年 | 135篇 |
1977年 | 94篇 |
1976年 | 103篇 |
1975年 | 91篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
41.
重组人白细胞介素10的融合表达及鉴定 总被引:1,自引:0,他引:1
目的 研究重组人白细胞介素10(rhIL—10)载体在大肠杆菌B121(DE3)pLyse细胞中的表达,为进一步研究IL-l0在动脉粥样硬化中的作用机制奠定基础。方法 用构建成功的IL-l0—PCRT7/NT-TOPO质粒转化大肠杆菌BL21(DE3)pLyse细胞,并通过SDS-PAGE鉴定融合表达蛋白。结果 PCRT7/NT—TOPO质粒载体成功载入rhIL-l0基因;在异丙基硫代—β-D-半乳糖苷(IPTG)诱导下表达的蛋白质主要以包涵体形式存在。结论 在IPTG诱导下,重组的IL-l0—PCRT7/NT—TOPO质粒载体在大肠杆菌BL2l(DE3)pLyse细胞内成功表达。 相似文献
42.
43.
44.
The effect of Panaxatriol Ginsenoside (PTGS) on Immune functions in bone marrow suppressed mice induced by injection of cyclophosphamide (CY) has been studied. Bone marrow suppressed mice were made by injection of CY (150 mg/kg) parenterally. Subcutaneous injection of PTGS three days earlier partially restored the number and the activity of bone marrow cells, significantly enhanced the production of IL-1, IL- 3 and IL- 6 like substances and promoted the reactivity of murlne spleen cells to Con-A In bone marrow suppressed mice. 相似文献
45.
短暂性脑缺血发作患者血浆中TXB2和PGF1α含量检测 总被引:3,自引:0,他引:3
本文用放射免疫法测定47例短暂性脑缺血发作(TIA)患者血浆中血栓素B_2(TXB_2)和6酮-前列腺F_(1α)(PGF_(1α))的含量。结果发现TIA患者血浆中TXB_2含量增高,PGF_(1α)降低;头颅CT或MRI示有小灶性梗塞者及TIA发作持续时间长于30min者TXB_2升高和PGF_(1α)降低更显著。治疗3个月后,血浆PGF_(1α)显著增高。TXB_2和PGF_(1α)在体内的失平衡是急性脑血管疾病发病的重要机理之一。 相似文献
46.
Eric Vivier Antonio J. da Silva Melissa Ackerly Herbert Levine Christopher E. Rudd Paul Anderson 《European journal of immunology》1993,23(8):1872-1876
The CD16: ζ: γ receptor complex allows natural killer (NK) cells to recognize and eliminate antibody-coated target cells. Whereas the ectodomain of CD16 is the receptor for Fcγ domains of immunoglobulins, disulfide-linked homo- and heterodimers composed of ζ and γ are required for the cell surface expression, and signal transduction properties of the complex. Engagement of CD16 activates the tyrosine kinase pathway, which induces the tyrosine phosphorylation of several substrates, including the ζ subunit and the phospholipase C γ-1 and γ-2 isoforms. Here we show that CD 16 stimulation of either peripheral blood NK cells, leukemic NK cells, or Jurkat transformants expressing a CD16:ζ:γ receptor complex, results in the tyrosine phosphorylation of a 70 kDa ζ-associated protein (pp70). Similarly, a 70-kDa ζ-associated phosphoprotein in T cells has been shown to be a tyrosine kinase (ZAP-70). Peptide mapping analysis indicates that the 70-kDa ζ-associated phosphoproteins from T cells and NK cells are structurally indistinguishable. We conclude that the CD16:ζ:γ complex may use a ZAP-70-related non-receptor tyrosine kinase, in the CD16 signaling cascade leading to NK cell activation. 相似文献
47.
48.
目的:比较正常肝组织与肝癌AH 109A,吉田肉瘤中谷氨酸脱氢酶,胆碱氧化酶和葡萄糖-6-磷酸酶的活力对~(67)Ga摄取与积累的影响;方法:制备~(67)Ga枸橼酸溶液给大鼠静注后处死大鼠,制备亚细胞悬液,液闪计数器测定放射活度.结果:~(67)Ga的放射活性在正常肝组织溶酶体中(55%积聚)显著高于肝癌AH109A(32%积聚)和吉田肉瘤(18%)积聚.谷氨酸脱氢酶的活力在正常肝组织,肝癌和吉田肉瘤分别是1830±s 320 U·L~(-1),23±s 6 U·L~(-1)和7±s 2 U·L~(-1);胆碱氧化酶的活力分别是46±s 10 U·L~(-1),25.0±s 0.4 U·L~(-1),2.0±0.4 U·L~(-1);葡萄糖-6-磷酸酶活力分别是2550±s 180 U·L~(-1),84±s 14 U·L~(-1),78±s13 U·L~(-1).结论:正常肝组织中溶酶体酶活力很强,对~(67)Ga的积累起较大作用.癌变组织酶活力降低而作用减弱.吉田肉瘤细胞无肝细胞特点,其溶酶体对~(67)Ga积累作用不大. 相似文献
49.
50.
Dr. David M. Euhus MD Lucille Kimura PhD Bruce Arnold MD 《Annals of surgical oncology》1997,4(5):432-439
Background: Mice immunized with murine mammary carcinoma cells genetically engineered to secrete interleukin-2 (IL-2) are rendered resistant
to subsequent challenge with unmodified tumor cells, and in the case of mice bearing established tumors, the rate of development
of pulmonary metastases is reduced. Despite these encouraging animal results, little is known about the induction of antitumor
immunity by IL-2 gene transfer in human breast cancer.
Methods: Adenovirally mediated IL-2 gene transfer was performed in 12 tumor fragment cultures established from seven primary breast
cancers. Autologous tumor infiltrating lymphocytes (TILs) or peripheral blood mononuclear cells (PBMCs) were cocultured with
transduced tumor fragments, and changes in phenotype and cytotoxicity were measured.
Results: IL-2 was never detectable in the untransduced cultures, but it peaked at 5.0—1,324.8 ng/ml in the transduced cultures. Lymphocyte
counts declined in all untransduced cultures, but they increased two- to sevenfold in four transduced cultures. CD4:CD8 ratios
decreased from a mean of 2.11 at baseline to 1.27 after stimulation in coculture (p=0.03). Expansion of lymphocytes expressing
the natural killer cell phenotype (CD3−CD56+) occurred in only one culture, but the CD3+CD56+ population increased in four of six cultures. Lymphocytes from four of 10 cocultures generated significant cytotoxicity against
allogeneic breast cancer cells. Induction of cytotoxicity correlated with expansion of the CD3+CD56+ phenotype (R2=0.805, p=0.02).
Conclusions: IL-2 gene expression by human breast cancer causes expansion of CD3+CD56+ cytotoxic lymphocytes. This phenotype is consistent with that of a non-major histocompatibility complex (MHC)-restricted
cytokine induced killer cell population previously described.
Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the
U.S. Army.
Presented at the 49th Annual Cancer Symposium of The Society of Surgical Oncology, Atlanta, Georgia, March 21–24, 1996. 相似文献